Research Article

Increased Performances of the Biological Diagnosis of the Antiphospholipid Syndrome by the Use of a Multiplex Assay

Table 3

Odds ratio associated with positivity of the markers alone or combined, according to the clinical scores used. The disease rate corresponds to the percentage of patients of each studied group (according to their positivity for the indicated markers) presenting with the disease. (a) Analysis with the application of the APS-3 criteria (numbers of studied patients: 18 and 212 affected and nonaffected patients, resp.). (b) Analysis with the application of the APS-2/3 criteria (numbers of studied patients: 32 and 198 affected and nonaffected patients, resp.).
(a)

Studied groupNumber of cases
(APS/no APS)
Disease rate (%)Odds ratio 95% CI

APS-3
aCL+/B2+/LA
(9/1)9021124–1850 < 10−4
APS-3
aCL+/B2+
(13/7)657621–273 < 10−4
APS-3
aCL+/LA
(11/4)738220.8–322 < 10−4
APS-3
B2+/LA
(9/1)9021124–1850 < 10−4
APS-3
aCL+
(18/57)24NANANA
APS-3
B2+
(13/7)657621–273 < 10−4
APS-3
LA
(11/9)553511–113 < 10−4

(b)

Studied groupNumber of cases
(APS/no APS)
Disease rate (%)Odds ratio95% CI

APS-2/3
aCL+/B2+/LA
(9/1)9021124–1850 < 10−4
APS-2/3
aCL+/B2+
(16/4)804914–162 < 10−4
APS-2/3
aCL+/LA
(12/3)803910–150 < 10−4
APS-2/3
B2+/LA
(9/1)90779–636 < 10−4
APS-2/3
aCL+
(24/51)3293.7–20.5 < 10−4
APS-2/3
B2+
(16/4)804914–162 < 10−4
APS-2/3
LA
(13/7)65196.7–52 < 10−4